LIVE MARKET TRACKER :   BSE SENSEX   31138.21      |    NSE NIFTY 9574.95    
GLOBAL MARKETS :  NASDAQ 6265.2495   +0.4580%    |    FSI London 7424.13   -0.20%    |    NIKKEI Japan 20132.67   +0.11%
  USD GBP EUR CAD AUD INR
USD - 0.7870 0.8937 1.3274 1.3181 64.5290
GBP 1.2719 - 1.1368 1.6883 1.6757 82.0797
EUR 1.1189 0.8801 - 1.4782 1.4736 72.1941
CAD 0.7552 0.5936 0.6749 - 0.9949 48.6810
AUD 0.7575 0.5973 0.6786 1.0066 - 48.9610
INR 0.0155 0.0122 0.0139 0.0206 0.0205 -
Indian-Commodity  :  Corporate  :  Lupin Receives FDA approval for Potassium Chloride Extended Release Capsules

Lupin Receives FDA approval for Potassium Chloride Extended Release Capsules (17-Aug-2016)

Lupin's US subsidiary, Gavis Pharmaceuticals LLC., USA (collectively Lupin) has received final approval for its Potassium Chloride Extended Release Capsules USP, 8 mEq (600 mg) and 10 mEq (750 mg) from the United States Food and Drug Administration (FDA) to market a generic equivalent of Actavis Labs FL, Inc's Potassium Chloride Extended Release Capsules USP, 8 mEq and 10 mEq. Potassium Chloride Extended Release Capsules USP, 8 mEq and 10 mEq had US sales of USD 75.4 million as per IMS MAT March 2016 data.

Lupin's Potassium Chloride Extended Release Capsules USP, 8 mEq (600 mg) and 10 mEq (750 mg) are the AB rated generic equivalent of Actavis Labs FL, Inc's Potassium Chloride Extended Release Capsules USP, 8 mEq and 10 mEq. It is indicated for the treatment of patients with hypokalemia, with or without metabolic alkalosis, in digitalis intoxications and in patients with hypokalemic familial periodic paralysis. It is also indicated for the prevention of hypokalemia in patients who would be at a particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally.



Top News Today
Tata Steel sells stake in Tata Motors
(24-Jun-2017)

Tata Steel sells stake in Tata MotorsTata Steel has sold its stake in Tata Motors to Tata Sons, the holding company of India's salt-to-software Tata conglomerate, for Rs 37.83 billion ($586.3 million). The steelmaker has sold about 83.54......click on news to read complete article.

Crest Ventures acquires 6 lakh shares of Crest Wealth Management
(24-Jun-2017)

Crest Ventures acquires 6 lakh shares of Crest Wealth ManagementCrest Ventures (CVL) has acquired 6 lakh equity shares of Crest Wealth Management (CWMPL), its Subsidiary Company, from Mitesh Shah at a total consideration of Rs 43.20 lakh on June 23, 2017. Consequent......click on news to read complete article.

DPSC's arm to co-develop 12MW of solar assets in Uttarakhand
(24-Jun-2017)

DPSCDPSC's wholly owned subsidiary India Power Green Utility (IPGUPL) has agreed to co-develop 12MW of solar assets in Uttarakhand with Punj Lloyd Infrastructure (PLIL) to be executed by PL Surya Vidyut, the......click on news to read complete article.

International Stock News
US markets end mostly in green of Friday
(24-Jun-2017)

US markets end mostly in green of FridayThe US markets ended the choppy day of trade mostly in green on Friday, as traders took some support with report from the Commerce Department showing a rebound in new home sales in the month of May. The......click on news to read complete article.

US markets closed mostly lower on Thursday
(23-Jun-2017)

US markets closed mostly lower on ThursdayThe US markets closed mostly lower on Thursday, as weak financials and consumer staples shares eclipsed a rally in the health-care and biotechnology sectors. The Federal Reserve said that the 34 largest......click on news to read complete article.

US markets closed mostly lower; Nasdaq post moderate gains
(22-Jun-2017)

US markets closed mostly lower; Nasdaq post moderate gainsThe US markets closed lower on Wednesday, weighed down by losses in the energy sector as oil prices continued to slide. But the Nasdaq Composite posted moderate gains, thanks to a surge in biotechnology......click on news to read complete article.

 

     
  
Recent Corporate News
 
EquityInvestmentCompany ReportsIPO
Disclaimer
By clicking on this page you accept all the terms and conditions framed by us. News made available here are for informational purpose only. While utmost care has been taken in providing the same. We claim no responsibility for its accuracy. Readers of this blog who make their decision based on the information posted here are solely responsible for their actions.